Drugmaker Eli Lilly says experimental Alzheimer’s drug remternetug is part of the next generation of anti-amyloids. The approval of the controversial anti-amyloid drug Aduhelm…
A second patient has died of brain bleeds — an anti-amyloid side effect — during the clinical trial extension of Eisai’s Alzheimer’s treatment lecanemab…
In Phase 3 trials, Roche’s experimental Alzheimer’s drug gantenerumab has failed to meet its objectives for slowing cognitive decline. Most Alzheimer’s treatments on the market…
European drug regulators dealt a blow to Biogen, deciding against allowing Aduhelm onto the market. Meanwhile, the company slashed the price of its drug…